Ardelyx Inc
![Ardelyx Inc](https://api.admiralmarkets.com/trade_icons/bright-128/ARDX.png)
Closed
Sector Healthcare
5.62 2.18
Overview
Share price change
24h
Min
5.44
Max
5.75
Income | -33M -27M |
---|---|
Sales | 12M 46M |
EPS | -0.11 |
Profit margin | -57.619 |
Employees | 267 |
EBITDA | -30M -22M |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +84.34 upside |
Next Earnings | 1 sie 2024 |
---|
Market Cap | -21M 1.4B |
---|---|
Previous open | 3.44 |
Previous close | 5.62 |
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Ardelyx Inc Chart
Related News
Peer Comparison
Price change
Ardelyx Inc Forecast
Price Target
By TipRanks
84.34% upside
12 Months Forecast
Average 10.36 USD 84.34%
High 12.5 USD
Low 7 USD
Based on 7 Wall Street analysts offering 12 month price targets forArdelyx Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ardelyx Inc
Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.